Form 4: RELMADA Therapeutics COO and Director Paul Kelly Granted 400,000 Stock Options

Paul Edward Kelly, Chief Operating Officer and Director of RELMADA Therapeutics, Inc., was granted 400,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.

Summary

• Paul Edward Kelly, Chief Operating Officer and Director of RELMADA THERAPEUTICS, INC. (RLMD), acquired 400,000 stock options.
• The options have an exercise price of $0.67 per share.
• The transaction date for the option grant was June 26, 2025.
• The options begin vesting on September 26, 2025, in 16 equal quarterly installments.
• The options expire on June 26, 2035.
• Following this transaction, Paul Kelly beneficially owns 400,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign, indicating management's long-term commitment and alignment with shareholder interests. It's a routine compensation event, not indicative of major positive or negative news, but the incentive structure is positive.

Positives

• The grant of stock options to a key executive like the COO and Director aligns management's interests with shareholder value, as the options gain value if the stock price increases above the exercise price.
• The long vesting schedule, spanning 16 equal quarterly installments commencing September 26, 2025, encourages long-term commitment and performance from the executive.

Future Outlook

The vesting schedule for the stock options indicates a future commitment from the executive, aligning their long-term interests with the company's performance and potential growth over the next several years.

Industry Context

This is a standard executive compensation event, common across all industries for aligning management incentives with shareholder value. It does not provide specific insights into broader industry trends.

Comparison to Industry Standards

• The grant of stock options is a common form of executive compensation across various industries, designed to align executive interests with long-term shareholder value.
• Assessing the specific number of options (400,000) and the exercise price ($0.67) against industry standards would require detailed analysis of RELMADA Therapeutics' market capitalization, the executive's specific role and responsibilities, and compensation practices of comparable companies in the biotechnology or pharmaceutical sector, which is not provided in this filing.

Related Party Transactions

• The stock option grant to Paul Edward Kelly, a Director and Chief Operating Officer, constitutes a related party transaction as it involves compensation provided to a key management personnel.

Stakeholder Impact

• Shareholders: The grant aligns the COO's financial interests with shareholder value creation, as the options become more valuable if the stock price increases above the exercise price.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• The stock options will begin vesting in 16 equal quarterly installments starting September 26, 2025.
• Paul Kelly may exercise these options at any time after they vest and before their expiration date of June 26, 2035.

Key Dates

Recommendation

Keywords

RELMADA THERAPEUTICS, RLMD, Paul Edward Kelly, Stock Options, Insider Transaction, SEC Form 4, Executive Compensation, Beneficial Ownership, Derivative Securities